At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
REGN Regeneron Pharmaceuticals
Closed 06-26 16:00:00 EDT
632.90
+12.76
+2.06%
盘后633.09
+0.19+0.03%
19:57 EDT
High638.76Low623.44Vol1.21M
Open623.64D1 Closing620.14Amplitude2.47%
Mkt Cap66.91BTradable Cap65.38BTotal Shares105.72M
T/O768.57MT/O Rate1.17%Tradable Shares103.30M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Healthcare Stocks Have Become a Haven for Investors Ditching Tech
Dow Jones  ·  29 minutes ago
Healthcare Stocks Have Become a Haven for Investors Ditching Tech
Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day
Dow Jones  ·  04:45
Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day
How Investors May Respond To Regeneron Pharmaceuticals (REGN) Cemdisiran Priority Review for gMG Treatment
Simply Wall St.  ·  03:16
How Investors May Respond To Regeneron Pharmaceuticals (REGN) Cemdisiran Priority Review for gMG Treatment
Regeneron Updates Financial Calendar for Second-quarter Results Release and Conference Call
Reuters  ·  06-26 04:05
Regeneron Updates Financial Calendar for Second-quarter Results Release and Conference Call
Regeneron’s New First-in-Human Eczema Drug REGN20423: Early Trial Progress and Investor Takeaways
TIPRANKS  ·  06-26 00:31
Regeneron’s New First-in-Human Eczema Drug REGN20423: Early Trial Progress and Investor Takeaways
Kymera Rises on Accelerated Trial Timeline for Experimental Eczema Drug
Reuters  ·  06-25 19:49
Kymera Rises on Accelerated Trial Timeline for Experimental Eczema Drug
AbbVie is buying a biotech working on an experimental eczema drug for $10.9 billion
Dow Jones  ·  06-22
AbbVie is buying a biotech working on an experimental eczema drug for $10.9 billion
Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis
Dow Jones  ·  06-22
Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis
Regeneron says FDA accepts cemdisiran gMG filing for priority review
Reuters  ·  06-22
Regeneron says FDA accepts cemdisiran gMG filing for priority review
Regeneron Pharmaceuticals - FDA to Review Cemdisiran Nda Under Priority Review With Target Action Date November 2026
THOMSON REUTERS  ·  06-22
Regeneron Pharmaceuticals - FDA to Review Cemdisiran Nda Under Priority Review With Target Action Date November 2026
Regeneron Pharmaceuticals - European Commission Decision on Cemdisiran Expected in Second Half of 2027
THOMSON REUTERS  ·  06-22
Regeneron Pharmaceuticals - European Commission Decision on Cemdisiran Expected in Second Half of 2027
Cemdisiran Regulatory Submissions Accepted for Review by FDA and Ema for the Treatment of Generalized Myasthenia Gravis (Gmg)
THOMSON REUTERS  ·  06-22
Cemdisiran Regulatory Submissions Accepted for Review by FDA and Ema for the Treatment of Generalized Myasthenia Gravis (Gmg)
Regeneron Pharmaceuticals - Plans Regulatory Filing for Cemdisiran in Japan in Early 2027
THOMSON REUTERS  ·  06-22
Regeneron Pharmaceuticals - Plans Regulatory Filing for Cemdisiran in Japan in Early 2027
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
GlobeNewswire  ·  06-22
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
AbbVie would gain an experimental eczema drug by buying biotech: report
Dow Jones  ·  06-21
AbbVie would gain an experimental eczema drug by buying biotech: report
Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day
Dow Jones  ·  06-18
Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day
Regeneron Pharmaceuticals shareholders elect Class II directors at annual meeting
Reuters  ·  06-18
Regeneron Pharmaceuticals shareholders elect Class II directors at annual meeting
Regeneron (REGN) Stock Valuation After WHO Ebola Trial Backing And Expanding R&D Collaborations
Simply Wall St.  ·  06-13
Regeneron (REGN) Stock Valuation After WHO Ebola Trial Backing And Expanding R&D Collaborations
Parabilis Medicines Closes Initial Public Offering
MT Newswires Live  ·  06-12
Parabilis Medicines Closes Initial Public Offering
Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors
Dow Jones  ·  06-11
Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors

Introduction

Company Name.
Regeneron Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Issue price:
--